<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> often has an <z:hpo ids='HP_0003587'>insidious onset</z:hpo> with <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> being present for many years before diagnosis is made </plain></SENT>
<SENT sid="1" pm="."><plain>It is a progressive disease, due in part to loss of beta-cell function, with the reduction in function probably commencing 10-12 years prior to diagnosis and being aggravated by increasing fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> levels </plain></SENT>
<SENT sid="2" pm="."><plain>Earlier intervention in those at risk from type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, aimed at minimizing <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, may prevent or delay overt <z:mp ids='MP_0002055'>diabetes</z:mp> and the associated development of micro- and macrovascular disease </plain></SENT>
<SENT sid="3" pm="."><plain>Six-year follow-up data from the UK Prospective <z:mp ids='MP_0002055'>Diabetes</z:mp> Study, confirm that sulphonylurea, <z:chebi fb="0" ids="6801">metformin</z:chebi> and insulin therapy can reduce <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> in individuals with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Although none of these agents prevent the subsequent progressive increase in fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> levels, preliminary results with <z:chebi fb="0" ids="2376">acarbose</z:chebi> show that fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> levels can be maintained over 1 year of therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Three large-scale studies are currently investigating whether treatment with <z:chebi fb="0" ids="2376">acarbose</z:chebi> at an earlier stage of the disease process, in subjects with varying degrees of <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo>, may be beneficial in helping to prevent or delay the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>